A comprehensive insight into baicalein and baicalin: neuroprotective perspectives in Alzheimer’s disease

Abstract

The investigations pertaining to the effectiveness of natural products in novel drug development for the prevention of a myriad of neurodegenerative diseases are offering encouraging prospects in novel drug development. This review endeavors to offer a comprehensive insight into the neuroprotective effects of baicalein (BE) and baicalin (BI), bioactive flavonoids found in Scutellaria baicalensis, primarily from the perspective of Alzheimer’s disease (AD). It systematically encompasses the scientifically pertinent investigations on BE’s prospective benefits in AD models, highlighting its mechanistic approaches and impending therapeutic applications in the amelioration of AD. The multifaceted pharmacological interventions offered by these bioactives, including antioxidant, anti-inflammatory, and immunomodulation effects, reinforce the scientific evidence supporting them as promising candidates for anti-AD agents and for preventing and managing other allied neurodegenerative disorders. These findings suggest that BE and BI, along with other nutraceuticals, may offer a valuable therapeutic strategy for improving symptoms and slowing disease progression in neurodegenerative disorders. Thus, the review intends to offer comprehensive illustrations warranting further investigation to corroborate the safety and efficacy of these bioactives in clinical settings. The researchers are progressively entrusting nature’s own compounds for the treatment of neurodegeneration. Conclusively, this manuscript could aptly serve as an insight to embark upon the remarkable pharmacological actions of these bioactives, which might be harnessed to prevent and manage AD. Nevertheless, the findings so far are promising; still, further investigations are incumbent to establish their safety and efficacy in humans, as BE and BI may offer novel modalities to circumvent this devastating disease.

Keywords

amyloid-beta / Alzheimer’s disease / baicalein / baicalin / dementia / neuroprotection / Oroxylum indicum / Scutellaria baicalensis

References

[1] Dementia [Internet]. Geneva: World Health Organization; c2025 [cited 2025 Jun 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia

[2] World Alzheimer Report 2023: Reducing dementia risk: never too early, never too late [Internet]. London: Alzheimer’s Disease International; [cited 2025 Jun 17]. Available from: https://www.alzint.org/resource/world-alzheimer-report-2023/

[3] 2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024; 20: 3708-821.

[4] Nandi A, Counts N, Bröker J, Malik S, Chen S, Han R, et al. Cost of care for Alzheimer’s disease and related dementias in the United States: 2016 to 2060. NPJ Aging. 2024; 10: 13.

[5] World Alzheimer Report 2024: Global changes in attitudes to dementia [Internet]. London: Alzheimer’s Disease International; [cited 2025 Jun 19]. Available from: https://www.alzint.org/resource/world-alzheimer-report-2024/

[6] Brockmann R, Nixon J, Love BL, Yunusa I. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer’s disease: patient outcomes, healthcare costs, and drug development. Lancet Reg Health Am. 2023; 20: 100467.

[7] Mahase E. Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns. BMJ. 2023; 380: 73.

[8] Cirrito JR, Holtzman DM. Amyloid β and Alzheimer disease therapeutics: the devil may be in the details. J Clin Invest. 2003; 112: 321-3.

[9] Aghajanzadeh M, Andalib S, Danafar H, Rostamizadeh K, Sharafi A. The effect of baicalein-loaded Y-shaped miktoarm copolymer on spatial memory and hippocampal expression of DHCR24, SELADIN and SIRT6 genes in rat model of Alzheimer. Int J Pharm. 2020; 586: 119546.

[10] Karran E, Strooper BD. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022; 21: 306-18.

[11] Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Sig Transduct Target Ther. 2023; 8: 248.

[12] Arnsten AFT, Datta D, Tredici KD, Braak H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimers Dement. 2021; 17: 115-24.

[13] Chen Z, Huang J, Yang S, Hong F. Role of Cholinergic Signaling in Alzheimer’s Disease. Molecules. 2022; 27: 1816.

[14] Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH. Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation. 2023; 46: 1-17.

[15] Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer’s disease pathogenesis. Alzheimers Dement. 2023; 19: 333-42.

[16] Dhapola R, Beura SK, Sharma P, Singh SK, HariKrishnaReddy D. Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep. 2024; 51: 48.

[17] Apátiga-Pérez R, Soto-Rojas LO, Campa-Córdoba BB, Luna-Viramontes NI, Cuevas E, Villanueva-Fierro I, et al. Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer’s disease. Metab Brain Dis. 2022; 37: 39-50.

[18] Sędzikowska A, Szablewski L. Insulin and Insulin Resistance in Alzheimer’s Disease. Int J Mol Sci. 2021; 22: 9987.

[19] Feringa FM, van der Kant R. Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects. Front Aging Neurosci. 2021; 13: 690372.

[20] Liu R. Aging, Cellular Senescence, and Alzheimer’s Disease. Int J Mol Sci. 2022; 23: 1989.

[21] Zhang B, Chen T, Cao M, Yuan C, Reiter RJ, Zhao Z, et al. Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer’s Disease and Obesity. Front Immunol. 2022; 13: 900132.

[22] Kozhakhmetov S, Kaiyrlykyzy A, Jarmukhanov Z, Vinogradova E, Zholdasbekova G, Alzhanova D, et al. Inflammatory Manifestations Associated With Gut Dysbiosis in Alzheimer’s Disease. Int J Alzheimers Dis. 2024; 2024: 9741811.

[23] Andrews SJ, Renton AE, Fulton-Howard B, Podlesny-Drabiniok A, Marcora E, Goate AM. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. EBioMedicine. 2023; 90: 104511.

[24] Cavallucci V, D’Amelio M, Cecconi F. Aβ toxicity in Alzheimer’s disease. Mol Neurobiol. 2012; 45: 366-78.

[25] Wang K, Chen X. Protective effect of flavonoids on oxidative stress injury in Alzheimer’s disease. Nat Prod Res. 2025; 39: 1272-99.

[26] Patwardhan B, Vaidya AD, Chorghade M. Ayurveda and natural-product drug discovery. Curr Sci. 2004; 86: 789-99.

[27] Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001; 109: 69-75.

[28] Shang X, He X, He X, Li M, Zhang R, Fan P, et al. The genus Scutellaria an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2010; 128: 279-313.

[29] Zhao Q, Chen X, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull (Beijing). 2016; 61: 1391-8.

[30] Liang W, Huang X, Chen W. The Effects of Baicalin and Baicalein on Cerebral Ischemia: A Review. Aging Dis. 2017; 8: 850-67.

[31] Guo F, Li C, Dou J, Liang J, Chen Z, Xu Z, et al. Research progress on pharmacological properties and application of probiotics in the fermentation of Scutellaria baicalensis Georgi. Front Nutr. 2024; 11: 1407182.

[32] Eiden M, Leidel F, Strohmeier B, Fast C, Groschup MH. A Medicinal Herb Scutellaria lateriflora Inhibits PrP Replication in vitro and Delays the Onset of Prion Disease in Mice. Front Psychiatry. 2012; 3: 9.

[33] Chen L, Games DE, Jones J. Isolation and identification of four flavonoid constituents from the seeds of Oroxylum indicum by high-speed counter-current chromatography. J Chromatogr A. 2003; 988: 95-105.

[34] Cui X, Shen Y, Jiang S, Qian D, Shang E, Zhu Z, et al. Comparative analysis of the main active components and hypoglycemic effects after the compatibility of Scutellariae Radix and Coptidis Rhizoma . J Sep Sci. 2019; 42: 1520-7.

[35] Dinda B, Mohanta BC, Arima S, Sato N, Harigaya Y. Flavonoids from the stem-bark of Oroxylum indicum . Nat Prod Sci. 2007; 13: 190-4.

[36] Li H, Jiang Y, Chen F. Separation methods used for Scutellaria baicalensis active components. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 812: 277-90.

[37] Lin CC, Shieh DE. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med. 1996; 24: 31-6.

[38] Xie L, Wang X, Basnet P, Matsunaga N, Yamaji S, Yang D, et al. Evaluation of variation of acteoside and three major flavonoids in wild and cultivated Scutellaria baicalensis roots by micellar electrokinetic chromatography. Chem Pharm Bull (Tokyo). 2002; 50: 896-9.

[39] Biswas KP, Ghosh E, editors. Bharater Bonoushodi. 2nd ed. Calcutta: Calcutta University; 1994. p. 858.

[40] Janjušević L, Karaman M, Šibul F, Tommonaro G, Iodice C, Jakovljević D, et al. The lignicolous fungus Trametes versicolor (L.) Lloyd (1920): a promising natural source of antiradical and AChE inhibitory agents. J Enzyme Inhib Med Chem. 2017; 32: 355-62.

[41] Liu R, Zhang Y, Li S, Liu C, Zhuang S, Zhou X, et al. Extraction and preparation of 5-lipoxygenase and acetylcholinesterase inhibitors from Astragalus membranaceus stems and leaves. J Sep Sci. 2023; 46: e2200812.

[42] Chen M, Wang F, Lei H, Yang Z, Li C. In Silico Insights into Micro-Mechanism Understanding of Extracts of Taxus Chinensis Fruits Against Alzheimer’s Disease. J Alzheimers Dis. 2024; 97: 727-40.

[43] Jelić D, Lower-Nedza AD, Brantner AH, Blazekovic B, Bian B, Yang J, et al. Baicalein and Baicalein Inhibit Src Tyrosine Kinase and Production of IL-6. J Chem. 2016; 2016: 2510621.

[44] Wen Y, Wang Y, Zhao C, Zhao B, Wang J. The Pharmacological Efficacy of Baicalin in Inflammatory Diseases. Int J Mol Sci. 2023; 24: 9317.

[45] Si L, Lai Y. Pharmacological mechanisms by which baicalin ameliorates cardiovascular disease. Front Pharmacol. 2024; 15: 1415971.

[46] Lai M, Hsiu S, Tsai S, Hou Y, Chao PL. Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats. J Pharm Pharmacol. 2003; 55: 205-9.

[47] Salleh NNHN, Othman FA, Kamarudin NA, Tan SC. The Biological Activities and Therapeutic Potentials of Baicalein Extracted from Oroxylum indicum: A Systematic Review. Molecules. 2020; 25: 5677.

[48] Zieniuk B, Uğur Ş. The therapeutic potential of baicalin and baicalein in breast cancer: a systematic review of mechanisms and efficacy. Curr Issues Mol Biol. 2025; 47: 181.

[49] Chen H, Gao Y, Wu J, Chen Y, Chen B, Hu J, et al. Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. Cancer Lett. 2014; 354: 5-11.

[50] Song Z, He C, Yu W, Yang M, Li Z, Li P, et al. Baicalin Attenuated A β_1-42-Induced Apoptosis in SH-SY5Y Cells by Inhibiting the Ras-ERK Signaling Pathway. Biomed Res Int. 2022; 2022: 9491755.

[51] Yin F, Liu J, Ji X, Wang Y, Zidichouski J, Zhang J. Baicalin prevents the production of hydrogen peroxide and oxidative stress induced by Aβ aggregation in SH-SY5Y cells. Neurosci Lett. 2011; 492: 76-9.

[52] Sreedharan S, Pande A, Pande A, Majeed M, Cisneros-Zevallos L. The Neuroprotective Effects of Oroxylum indicum Extract in SHSY-5Y Neuronal Cells by Upregulating BDNF Gene Expression under LPS Induced Inflammation. Nutrients. 2024; 16: 1887.

[53] Mairuae N, Connor JR, Buranrat B, Lee SY. Oroxylum indicum (L.) extract protects human neuroblastoma SH-SY5Y cells against β-amyloid-induced cell injury. Mol Med Rep. 2019; 20: 1933-42.

[54] El-Araby RE, Wasif K, Johnson R, Tu Q, Aboushousha T, Zhu ZX, et al. Establishment of a novel cellular model for Alzheimer’s disease in vitro studies. Exp Neurol. 2024; 378: 114820.

[55] França MB, Lima KC, Eleutherio ECA. Oxidative Stress and Amyloid Toxicity: Insights From Yeast. J Cell Biochem. 2017; 118: 1442-52.

[56] Dhakal S, Ramsland PA, Adhikari B, Macreadie I. Trans-Chalcone Plus Baicalein Synergistically Reduce Intracellular Amyloid Beta (Aβ₄₂) and Protect from Aβ₄₂ Induced Oxidative Damage in Yeast Models of Alzheimer’s Disease. Int J Mol Sci. 2021; 22: 9456.

[57] Pádua MS, Guil-Guerrero JL, Prates JAM, Lopes PA. Insights on the Use of Transgenic Mice Models in Alzheimer’s Disease Research. Int J Mol Sci. 2024; 25: 2805.

[58] Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, Strooper BD, et al. APP mouse models for Alzheimer’s disease preclinical studies. EMBO J. 2017; 36: 2473-87.

[59] Lee J, Han P. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol. 2013; 22: 84-95.

[60] van Heuvelen MJG, van der Lei MB, Alferink PM, Roemers P, van der Zee EA. Cognitive deficits in human ApoE4 knock-in mice: A systematic review and meta-analysis. Behav Brain Res. 2024; 471: 115123.

[61] Abhyankar SD, Luo Q, Hartman GD, Mahajan N, Corson TW, Oblak AL, et al. Retinal dysfunction in APOE4 knock-in mouse model of Alzheimer’s disease. Alzheimers Dement. 2025; 21: e14433.

[62] Dey S, Thamaraikani T, Vellapandian C. Advancing Alzheimer’s Research With Zebrafish Models: Current Insights, Addressing Challenges, and Charting Future Courses. Cureus. 2024; 16: e66935.

[63] Lemkul JA, Bevan DR. The role of molecular simulations in the development of inhibitors of amyloid β-peptide aggregation for the treatment of Alzheimer’s disease. ACS Chem Neurosci. 2012; 3: 845-56.

[64] Srivastava S, Sharma S, Deep S, Khare SK. Screening of Multitarget-Directed Natural Compounds as Drug Candidates for Alzheimer’s Disease Using In Silico Techniques: Their Extraction and In Vitro Validation. ACS Omega. 2023; 8: 38118-29.

[65] Ramakrishnan V, Friedrich C, Witt C, Sheehan R, Pryor M, Atwal JK, et al. Quantitative systems pharmacology model of the amyloid pathway in Alzheimer’s disease: Insights into the therapeutic mechanisms of clinical candidates. CPT Pharmacometrics Syst Pharmacol. 2023; 12: 62-73.

[66] Jarrell JT, Gao L, Cohen DS, Huang X. Network Medicine for Alzheimer’s Disease and Traditional Chinese Medicine. Molecules. 2018; 23: 1143.

[67] Zhang D, Shen D; Alzheimer’s Disease Neuroimaging Initiative. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One. 2012; 7: e33182.

[68] Jirsa VK, Stacey WC, Quilichini PP, Ivanov AI, Bernard C. On the nature of seizure dynamics. Brain. 2014; 137: 2210-30.

[69] Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem. 2017; 131: 68-80.

[70] Gasiorowski K, Lamer-Zarawska E, Leszek J, Parvathaneni K, Yendluri BB, Błach-Olszewska Z, et al. Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration? CNS Neurol Disord Drug Targets. 2011; 10: 184-91.

[71] Zhou L, Tan S, Shan Y, Wang Y, Cai W, Huang X, et al. Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats. Neuropsychiatr Dis Treat. 2016; 12: 3145-52.

[72] Zhang X, Li W, Li W, Ren K, Fan C, Chen Y, et al. Protective effects of the aqueous extract of Scutellaria baicalensis against acrolein-induced oxidative stress in cultured human umbilical vein endothelial cells. Pharm Biol. 2011; 49: 256-61.

[73] Wu C, Chen Y, Lu D, Hsu L, Yang K, Sumi S. Evaluation of the post-treatment anti-inflammatory capacity of osteoarthritic chondrocytes: An in vitro study using baicalein. Regen Ther. 2020; 14: 177-83.

[74] Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 2009; 35: 57-68.

[75] Kadir MF, Karmoker JR, Alam MR, Jahan SR, Mahbub S, Mia MMK. Ethnopharmacological survey of medicinal plants used by traditional healers and indigenous people in chittagong hill tracts, bangladesh, for the treatment of snakebite. Evid Based Complement Alternat Med. 2015; 2015: 871675.

[76] Dou J, Wang Z, Ma L, Peng B, Mao K, Li C, et al. Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. Oncotarget. 2018; 9: 20089-102.

[77] Liu Z, Zheng X, Li N, Wang Z. Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF-1α signaling. Mol Med Rep. 2025; 31: 18.

[78] Wang J, Wu Z, Peng J, You F, Ren Y, Li X, et al. Multiple roles of baicalin and baicalein in the regulation of colorectal cancer. Front Pharmacol. 2024; 15: 1264418.

[79] Scarlata GGM, Lopez I, Gambardella ML, Milanović M, Milić N, Abenavoli L. Preventive and Therapeutic Effects of Baicalein, Galangin, and Isorhamnetin in Chronic Liver Diseases: A Narrative Review. Molecules. 2025; 30: 1253.

[80] Hu Z, Guan Y, Hu W, Xu Z, Ishfaq M. An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways. Iran J Basic Med Sci. 2022; 25: 14-26.

[81] Xiong J, Wang C, Chen H, Hu Y, Tian L, Pan J, et al. Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway. Int J Neurosci. 2014; 124: 609-20.

[82] Ding L, Jia C, Zhang Y, Wang W, Zhu W, Chen Y, et al. Baicalin relaxes vascular smooth muscle and lowers blood pressure in spontaneously hypertensive rats. Biomed Pharmacother. 2019; 111: 325-30.

[83] Yu H, Zhu Y, Zhang X, Wang L, Zhou Y, Zhang F, et al. Baicalin attenuates amyloid β oligomers induced memory deficits and mitochondria fragmentation through regulation of PDE-PKA-Drp1 signalling. Psychopharmacology (Berl). 2022; 239: 851-65.

[84] Gao L, Zhou F, Wang K, Zhou Y, Du G, Qin X. Baicalein protects PC12 cells from Aβ_25-35-induced cytotoxicity via inhibition of apoptosis and metabolic disorders. Life Sci. 2020; 248: 117471.

[85] Lebeau A, Esclaire F, Rostène W, Pélaprat D. Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity. Neuroreport. 2001; 12: 2199-202.

[86] Ding H, Wang H, Zhao Y, Sun D, Zhai X. Protective Effects of Baicalin on Aβ₁₋₄₂-Induced Learning and Memory Deficit, Oxidative Stress, and Apoptosis in Rat. Cell Mol Neurobiol. 2015; 35: 623-32.

[87] Dinda B, Dinda M, Dinda S, De UC. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms. Eur J Med Chem. 2023; 258: 115629.

[88] Dogra A. Baicalein: unveiling the multifaceted marvel of hepatoprotection and beyond. J Asian Nat Prod Res. 2025; 27: 1223-35.

[89] Khodir SA, Ahmed F, Omara H, Nagy A, El-Aziz NA, Bayomi A, et al. Neuroprotective Impact of Baicalein on Scopolamine Induced Cognitive Deficits Targeting PI3K/Akt/NF-kB Pathway. Mansoura J Forensic Med Clin Toxicol. 2025; 33: 45-59.

[90] Li J, Zhao C, Guan D, Liu C. Study on the Molecular Mechanism of Baicalin Phosphorylation of Tau Protein Content in a Cell Model of Intervention Cognitive Impairment. Neuropsychiatr Dis Treat. 2025; 21: 309-22.

[91] Zhu JTT, Choi RCY, Chu GKY, Cheung AWH, Gao QT, Li J, et al. Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. J Agric Food Chem. 2007; 55: 2438-45.

[92] Qiu X, Huang R, Xie J, Luo S, Cheng X, Cui J, et al. Recent Advances in the Therapeutic Effects and Molecular Mechanisms of Baicalin. Biology (Basel). 2025; 14: 637.

[93] Lu S, Li C, Jin X, Zhu L, Shen J, Bai M, et al. Baicalin improves the energy levels in the prefrontal cortex of mice exposed to chronic unpredictable mild stress. Heliyon. 2022; 8: e12083.

[94] Liu ZSJ, Truong TTT, Bortolasci CC, Spolding B, Panizzutti B, Swinton C, et al. The potential of baicalin to enhance neuroprotection and mitochondrial function in a human neuronal cell model. Mol Psychiatry. 2024; 29: 2487-95.

[95] Hu Q, Hou S, Xiong B, Wen Y, Wang J, Zeng J, et al. Therapeutic Effects of Baicalin on Diseases Related to Gut-Brain Axis Dysfunctions. Molecules. 2023; 28: 6501.

[96] Pang H, Xue W, Shi A, Li M, Li Y, Cao G, et al. Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers. Clin Drug Investig. 2016; 36: 713-24.

[97] Hang Y, Qin X, Ren T, Cao J. Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2018; 17: 146.

[98] Orzechowska B, Chaber R, Wiśniewska A, Pajtasz-Piasecka E, Jatczak B, Siemieniec I, et al. Baicalin from the extract of Scutellaria baicalensis affects the innate immunity and apoptosis in leukocytes of children with acute lymphocytic leukemia. Int Immunopharmacol. 2014; 23: 558-67.

[99] Yu F, Huang S, Zhang H, Ye H, Chi H, Zou Y, et al. Effects of baicalin in CD4 + CD29 + T cell subsets of ulcerative colitis patients. World J Gastroenterol. 2014; 20: 15299-309.

[100] Farris P, Yatskayer M, Chen N, Krol Y, Oresajo C. Evaluation of efficacy and tolerance of a nighttime topical antioxidant containing resveratrol, baicalin, and vitamin e for treatment of mild to moderately photodamaged skin. J Drugs Dermatol. 2014; 13: 1467-72.

[101] Isola G, Matarese M, Ramaglia L, Iorio-Siciliano V, Cordasco G, Matarese G. Efficacy of a drug composed of herbal extracts on postoperative discomfort after surgical removal of impacted mandibular third molar: a randomized, triple-blind, controlled clinical trial. Clin Oral Investig. 2019; 23: 2443-53.

[102] Isola G, Polizzi A, Iorio-Siciliano V, Alibrandi A, Ramaglia L, Leonardi R. Effectiveness of a nutraceutical agent in the non-surgical periodontal therapy: a randomized, controlled clinical trial. Clin Oral Investig. 2021; 25: 1035-45.

[103] Shi J, Chen J, Xie X, Li Y, Ye W, Yao J, et al. Baicalein-corrected gut microbiota may underlie the amelioration of memory and cognitive deficits in APP/PS1 mice. Front Pharmacol. 2023; 14: 1132857.

[104] Brinza I, Ayoub IM, Eldahshan OA, Hritcu L. Baicalein 5,6-Dimethyl Ether Prevents Memory Deficits in the Scopolamine Zebrafish Model by Regulating Cholinergic and Antioxidant Systems. Plants (Basel). 2021; 10: 1245.

[105] Heo H, Shin Y, Cho W, Choi Y, Kim H, Kwon YK. Memory improvement in ibotenic acid induced model rats by extracts of Scutellaria baicalensis . J Ethnopharmacol. 2009; 122: 20-7.

[106] Wang S, Wang H, Chi C, Chen C, Liao J. Effects of baicalein on beta-amyloid peptide-(25-35)-induced amnesia in mice. Eur J Pharmacol. 2004; 506: 55-61.

[107] Zhang H, Liu Q, Ding S, Li H, Shang Y. Flavonoids From Stems and Leaves of Scutellaria Baicalensis Georgi Improve Composited Aβ-Induced Alzheimer’s Disease Model Rats’ Memory and Neuroplasticity Disorders. Comb Chem High Throughput Screen. 2023; 26: 1519-32.

[108] Shengkai D, Yazhen S. Flavonoids from Stems and Leaves of Scutellaria baicalensis Georgi Regulate the Brain Tau Hyperphosphorylation at Multiple Sites Induced by Composited Aβ in Rats. CNS Neurol Disord Drug Targets. 2022; 21: 367-74.

[109] Zhai J, Hao C, Wang X, Cao Y, Pan Y, Zhou M, et al. Design, synthesis, and evaluation of dual-target inhibitors for the treatment of Alzheimer’s disease. Arch Pharm (Weinheim). 2024; 357: e2300693.

[110] Lin T, Tsai H, Lee C, Song Y, Huang R, Hsieh-Li H, et al. An Improved Drugs Screening System Reveals that Baicalein Ameliorates the Aβ/AMPA/NMDA-Induced Depolarization of Neurons. J Alzheimers Dis. 2017; 56: 959-76.

[111] Han J, Ji Y, Youn K, Lim G, Lee J, Kim DH, et al. Baicalein as a Potential Inhibitor against BACE1 and AChE: Mechanistic Comprehension through In Vitro and Computational Approaches. Nutrients. 2019; 11: 2694.

[112] Wei D, Tang J, Bai W, Wang Y, Zhang Z. Ameliorative effects of baicalein on an amyloid-β induced Alzheimer’s disease rat model: a proteomics study. Curr Alzheimer Res. 2014; 11: 869-81.

[113] Kaur G, Mankoo OK, Kaur A, Goyal D, Goyal B. Insights into the baicalein-induced destabilization of LS-shaped Aβ₄₂ protofibrils using computer simulations. Phys Chem Chem Phys. 2024; 26: 16674-86.

[114] Gauci AJ, Caruana M, Giese A, Scerri C, Vassallo N. Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Aβ₄₂ aggregates. J Alzheimers Dis. 2011; 27: 767-79.

[115] Caruana M, Neuner J, Högen T, Schmidt F, Kamp F, Scerri C, et al. Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro . Biochim Biophys Acta. 2012; 1818: 2502-10.

[116] Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils. J Biol Chem. 2004; 279: 26846-57.

[117] Williams SM, Schulz P, Sierks MR. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson’s and Alzheimer’s diseases. Eur J Neurosci. 2016; 43: 3-16.

[118] Wirths O, Bayer TA. α-synuclein, Aβ and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 103-8.

[119] Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998; 153: 1365-70.

[120] Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol. 2000; 10: 378-84.

[121] Swirski M, Miners JS, de Silva R, Lashley T, Ling H, Holton J, et al. Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease. Alzheimers Res Ther. 2014; 6: 77.

[122] Lu J, Ardah MT, Durairajan SSK, Liu L, Xie L, Fong WD, et al. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation. Chembiochem. 2011; 12: 615-24.

[123] Sonawane SK, Balmik AA, Boral D, Ramasamy S, Chinnathambi S. Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers. Arch Biochem Biophys. 2019; 675: 108119.

[124] Sonawane SK, Uversky VN, Chinnathambi S. Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation. Cell Commun Signal. 2021; 19: 16.

[125] Gu X, Xu L, Liu Z, Wei B, Yang Y, Xu G, et al. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer’s disease. Behav Brain Res. 2016; 311: 309-21.

[126] Heo HJ, Kim D, Choi SJ, Shin DH, Lee CY. Potent Inhibitory effect of flavonoids in Scutellaria baicalensis on amyloid β protein-induced neurotoxicity. J Agric Food Chem. 2004; 52: 4128-32.

[127] Moslehi M, Meshkini A, Yazdanparast R. Flavonoid baicalein modulates H₂O₂-induced mitogen-activated protein kinases activation and cell death in SK-N-MC cells. Cell Mol Neurobiol. 2012; 32: 549-60.

[128] Choi JH, Choi AY, Yoon H, Choe W, Yoon K, Ha J, et al. Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis through inhibition of reactive oxygen species production and CHOP induction. Exp Mol Med. 2010; 42: 811-22.

[129] Cho J, Hong E, Kim Y, Song J, Ju YH, Kim H, et al. Baicalin and baicalein from Scutellaria baicalensis Georgi alleviate aberrant neuronal suppression mediated by GABA from reactive astrocytes. CNS Neurosci Ther. 2024; 30: e14740.

[130] Darwish SF, Elbadry AMM, Elbokhomy AS, Salama GA, Salama RM. The dual face of microglia (M1/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases. Front Aging. 2023; 4: 1231706.

[131] Gong Q, Wang Y, Wang X, Pan H, Yan C. Baicalein promotes the microglia M2 polarization and suppresses apoptosis by targeting HMOX1/PDE4D to alleviate Alzheimer’s disease. Immunobiology. 2023; 228: 152761.

[132] Xie X, Hao J, Shi J, Zhou Y, Liu P, Wang F, et al. Baicalein ameliorates Alzheimer’s disease via orchestration of CX3CR1/NF-κB pathway in a triple transgenic mouse model. Int Immunopharmacol. 2023; 118: 109994.

[133] Shi J, Li Y, Zhang Y, Chen J, Gao J, Zhang T, et al. Baicalein Ameliorates Aβ-Induced Memory Deficits and Neuronal Atrophy via Inhibition of PDE2 and PDE4. Front Pharmacol. 2021; 12: 794458.

[134] Peng Y, Zhou C. Network Pharmacology and Molecular Docking Identify the Potential Mechanism and Therapeutic Role of Scutellaria baicalensis in Alzheimer’s Disease. Drug Des Devel Ther. 2024; 18: 1199-219.

[135] Yao Y, Liu Q, Ding S, Chen Y, Song T, Shang Y. Scutellaria baicalensis Georgi stems and leaves flavonoids promote neuroregeneration and ameliorate memory loss in rats through cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis. Heliyon. 2024; 10: e27161.

[136] Liao Y, Hu X, Pan J, Zhang G. Inhibitory Mechanism of Baicalein on Acetylcholinesterase: Inhibitory Interaction, Conformational Change, and Computational Simulation. Foods. 2022; 11: 168.

[137] Congcong X, Yuanyuan Y, Caixia L, Yazhen S. The Effects and Mechanism of Scutellaria baicalensis Georgi Stems and Leaves Flavonoids on Myelin Sheath Degeneration Induced by Composite Aβ in Rats. CNS Neurol Disord Drug Targets. 2024; 23: 504-11.

[138] Chen S, Corteling R, Stevanato L, Sinden J. Natural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cells. Biochem Biophys Res Commun. 2012; 429: 117-23.

[139] Choi RCY, Zhu JTT, Yung AWY, Lee PSC, Xu SL, Guo AJY, et al. Synergistic Action of Flavonoids, Baicalein, and Daidzein in Estrogenic and Neuroprotective Effects: A Development of Potential Health Products and Therapeutic Drugs against Alzheimer’s Disease. Evid Based Complement Alternat Med. 2013; 2013: 635694.

[140] Ji Y, Han J, Lee N, Yoon J, Youn K, Ha HJ, et al. Neuroprotective Effects of Baicalein, Wogonin, and Oroxylin A on Amyloid Beta-Induced Toxicity via NF-κB/MAPK Pathway Modulation. Molecules. 2020; 25: 5087.

[141] Jadhav R, Kulkarni YA. Effects of baicalein with memantine on aluminium chloride-induced neurotoxicity in Wistar rats. Front Pharmacol. 2023; 14: 1034620.

[142] Malik J, Mandal SC, Choudhary S, Parihar S, Rahamathulla M. Herbal Medicines for Management of Alzheimer’s Disease. In: Dhara AK, Mandal SC, editors. Role of Herbal Medicines. Singapore: Springer; 2023.

[143] Jin X, Liu M, Zhang D, Zhong X, Du K, Qian P, et al. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway. CNS Neurosci Ther. 2019; 25: 575-90.

[144] Chen C, Li X, Gao P, Tu Y, Zhao M, Li J, et al. Baicalin attenuates Alzheimer-like pathological changes and memory deficits induced by amyloid β_1-42 protein. Metab Brain Dis. 2015; 30: 537-44.

[145] Zhao J, Hou S, Zhao J, Yu H, Duan S. An interventional study of baicalin on neuronal pentraxin-1, neuronal pentraxin-2, and C-reactive protein in Alzheimer’s disease rat model. Transl Neurosci. 2023; 14: 20220298.